Published in Cancer Res on November 15, 2000
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
Androgen receptor signaling and mutations in prostate cancer. Asian J Androl (2010) 1.27
Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor. J Biol Chem (2010) 0.98
The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity. PLoS One (2012) 0.92
Androgen receptor mutations and polymorphisms in African American prostate cancer. Int J Biol Sci (2014) 0.87
Identification of a novel germline missense mutation of the androgen receptor in African American men with familial prostate cancer. Asian J Androl (2010) 0.86
Genetic and epigenetic changes in human prostate cancer. Iran Red Crescent Med J (2011) 0.79
Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 25.41
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science (1992) 16.38
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (1997) 8.05
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci U S A (1994) 5.74
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res (2001) 5.11
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer (1998) 4.22
Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res (1997) 4.02
Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res (1995) 3.98
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res (2000) 3.83
Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol (2001) 3.83
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun (1990) 3.79
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet (2002) 3.67
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res (1999) 3.41
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst (2000) 3.12
Aggressiveness of screen-detected breast cancers. Lancet (1995) 3.07
Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet (1998) 2.90
Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A (1998) 2.80
Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res (1999) 2.79
Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol (1991) 2.54
Ribosomal precursor particles from yeast. Exp Cell Res (1975) 2.41
Inferring tree models for oncogenesis from comparative genome hybridization data. J Comput Biol (1999) 2.25
Genome screening by comparative genomic hybridization. Trends Genet (1997) 2.23
High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol (1999) 2.22
The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol (1992) 2.21
Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer (2001) 2.17
Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res (2000) 2.13
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res (1998) 2.10
Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer (1999) 2.05
Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem (1996) 2.05
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res (1997) 2.03
Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem (1995) 2.02
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst (1992) 1.94
A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J Biol Chem (1999) 1.92
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res (1996) 1.89
Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst (2000) 1.86
An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol (1997) 1.85
High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol (2000) 1.82
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol (1995) 1.81
Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst (1999) 1.81
Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer (1991) 1.81
Computer image analysis of comparative genomic hybridization. Cytometry (1995) 1.80
Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res (2000) 1.78
A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. Lab Invest (1997) 1.74
Maturation of ribosomes in yeast. I Kinetic analysis by labelling of high molecular weight rRNA species. Biochim Biophys Acta (1976) 1.74
The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol (1991) 1.72
Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene (2011) 1.71
Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol (1999) 1.68
Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci U S A (2000) 1.66
Serum CA 125 in acute pelvic inflammatory disease. Br J Obstet Gynaecol (1989) 1.62
Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet (2005) 1.61
Colonic volvulus. Diagnosis and results of treatment in 82 patients. Eur J Surg (1993) 1.61
Nuclear import of the human androgen receptor. Biochem J (1993) 1.58
Distance-based reconstruction of tree models for oncogenesis. J Comput Biol (2000) 1.55
CHEK2 variants associate with hereditary prostate cancer. Br J Cancer (2003) 1.54
Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet (1997) 1.53
Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene (2006) 1.53
Nifedipine for suspected type II sphincter of Oddi dyskinesia. Am J Gastroenterol (1993) 1.51
Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol (2000) 1.47
Does defecography help in diagnosis and clinical decision-making in defecation disorders? Abdom Imaging (1994) 1.47
Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. Eur J Cancer Clin Oncol (1987) 1.46
Construction of evolutionary tree models for renal cell carcinoma from comparative genomic hybridization data. Cancer Res (2000) 1.45
Evidence for a protective role of interferon in resistance to murine cytomegalovirus and its control by non-H-2-linked genes. Infect Immun (1982) 1.44
Liver involvement in patients operated for ulcerative colitis, with special reference to the association of cholangitis with colorectal dysplasia and carcinoma. Int J Colorectal Dis (2000) 1.43
Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol (2001) 1.43
Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes Cancer (1995) 1.40
The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol (2006) 1.40
Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses. Proc Natl Acad Sci U S A (1995) 1.40
Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene (2001) 1.40
Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. Cytometry (1994) 1.39
Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res (1995) 1.38
The N-terminal domain of the human androgen receptor is encoded by one, large exon. Mol Cell Endocrinol (1989) 1.38
Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer. Genes Chromosomes Cancer (1997) 1.37
Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst (1992) 1.36
Trinucleotide repeat polymorphism in the androgen receptor gene (AR). Nucleic Acids Res (1992) 1.34
The interferon-stimulated gene 54 K promoter contains two adjacent functional interferon-stimulated response elements of different strength, which act synergistically for maximal interferon-alpha inducibility. Eur J Biochem (1994) 1.33
Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur J Hum Genet (2000) 1.27
Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol (1993) 1.26
ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res (2001) 1.26
ANX7, a candidate tumor suppressor gene for prostate cancer. Proc Natl Acad Sci U S A (2001) 1.26
Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol Endocrinol (1998) 1.26
A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. Genomics (1995) 1.24